Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2018 - 2026)

Amneal Pharmaceuticals' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $78.0 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 216.84% year-over-year to $78.0 million in Q1 2026; TTM through Mar 2026 was $181.3 million, a 459.27% increase from a year earlier, with the FY2025 full-year figure at $127.9 million, up 209.45% from the prior year.
• Net Income towards Common Stockholders rose to $78.0 million in Q1 2026 per AMRX's latest filing, from $49.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $78.0 million in Q1 2026 and bottomed at -$120.8 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is $9.7 million (2023), against an average of -$4.8 million.
• Biggest YoY gain for Net Income towards Common Stockholders was 460.06% in 2023; the steepest drop was 2176.69% in 2023.
• Year by year, Net Income towards Common Stockholders stood at -$4.3 million in 2022, then tumbled by 2176.69% to -$98.6 million in 2023, then jumped by 78.97% to -$20.7 million in 2024, then soared by 339.0% to $49.6 million in 2025, then soared by 57.34% to $78.0 million in 2026.
• Per Business Quant, the three latest AMRX Net Income towards Common Stockholders figures stand at $78.0 million (Q1 2026), $49.6 million (Q4 2025), and $18.1 million (Q3 2025).